Swedish Medical Center and University of Washington School of Medicine, Seattle, USA.
Arthritis Care Res (Hoboken). 2011 Jun;63(6):821-6. doi: 10.1002/acr.20449.
To estimate the minimum clinically important difference (MCID) for several pain measures obtained from the Brief Pain Inventory (BPI) for patients with fibromyalgia.
Data were pooled across 12-week treatment periods from 4 randomized, double-blind, placebo-controlled studies designed to evaluate the safety and efficacy of duloxetine for the treatment of fibromyalgia. Each study enrolled subjects with American College of Rheumatology--defined fibromyalgia who presented with moderate to severe pain. The MCIDs for the BPI average pain item score and the BPI severity score (the mean of the BPI pain scale values: right now, average, least, and worst) were estimated by anchoring against the Patient's Global Impressions of Improvement scale.
The anchor-based MCIDs for the BPI average pain item and severity scores were 2.1 and 2.2 points, respectively. These MCIDs correspond to 32.3% and 34.2% reductions from baseline in scores.
In these analyses, the MCIDs for several pain measures obtained from the BPI were similar (∼2 points) and corresponded to a 30-35% improvement from baseline to end point. These findings may be beneficial for use in designing clinical trials in which the BPI is used to evaluate improvements in pain severity.
评估纤维肌痛患者从简明疼痛量表（BPI）获得的几种疼痛测量值的最小临床重要差异（MCID）。
来自四项为期 12 周的随机、双盲、安慰剂对照研究的数据被汇总，这些研究旨在评估度洛西汀治疗纤维肌痛的安全性和疗效。每个研究都招募了符合美国风湿病学会定义的纤维肌痛且有中度至重度疼痛的患者。BPI 平均疼痛项目评分和 BPI 严重程度评分（BPI 疼痛量表值的平均值：现在、平均、最小和最差）的 MCID 通过与患者总体印象改善量表进行锚定来估计。
BPI 平均疼痛项目和严重程度评分的基于锚定的 MCID 分别为 2.1 和 2.2 分。这些 MCID 分别对应于从基线到评分的 32.3%和 34.2%的减少。
在这些分析中，BPI 获得的几种疼痛测量值的 MCID 相似（约 2 分），与从基线到终点的 30-35%的改善相对应。这些发现可能有助于在使用 BPI 评估疼痛严重程度改善的临床试验中设计。
